摘要
目的探究分析ISS分期与FISH技术对多发性骨髓瘤患者临床治疗效果及预后意义。方法选取2014年6月—2018年6月来本院就诊的91例多发性骨髓瘤患者作为研究对象,所有患者均给予硼替佐米诱导治疗,回顾性分析所有患者确诊时FISH检测结果、ISS分期情况、临床疗效以及生存时间情况,比较不同ISS分期多发性骨髓瘤患者各项实验室指标、临床疗效以及生存时间差异,分析ISS分期与FISH检测技术对多发性骨髓瘤患者临床治疗效果及预后影响。结果 91例多发性骨髓瘤患者中,ISSⅠ期患者20例,ISSⅡ期患者37例,ISSⅢ期患者34例。ISSⅢ期多发性骨髓瘤患者的FISH阳性检出率、FISH多阳性检出率均明显高于ISSⅠ期和ISSⅡ期患者(P<0.05),ISSⅡ期多发性骨髓瘤患者的FISH阳性检出率、FISH多阳性检出率则明显高于ISSⅠ期患者(P<0.05),差异具有统计学意义。ISSⅢ期患者完全缓解率明显低于ISSⅠ期、ISSⅡ期患者(P<0.05),其病情稳定率则明显偏高(P<0.05),ISSⅡ期患者的完全缓解率明显低于ISSⅠ期患者(P<0.05),其完全缓解率则明显高于ISSⅠ期患者(P<0.05),差异具有统计学意义。ISSⅢ期患者的中位生存时间明显短于ISSⅠ期和ISSⅡ期患者(P<0.05),ISSⅡ期患者的中位生存时间则明显较ISSⅠ期患者短(P<0.05),差异具有统计学意义。Pearson检验分析结果显示,多发性骨髓瘤患者的ISS分期与FISH结果阳性率、FISH多阳性检出率、病情稳定率呈明显的正相关,相关系数r=0.5321,P<0.05,患者ISS分期与临床完全缓解率以及中位生存时间则呈明显的负相关,相关系数r=0.4432,P<0.05,且多发性骨髓瘤患者的FISH阳性检出率与临床完全缓解率以及中位生存时间呈明显的负相关,相关系数r=0.3728,P<0.05。结论多发性骨髓瘤患者的ISS分期与患者FISH阳性检出率、FISH多阳性检出率、病情稳定率呈正相关,与患者临床完全缓解率以及中位生存时间则呈负相关,且患者的FISH阳性检出率与临床完全缓解率以及中位生存时间则呈负相关,临床ISS分期结果与FISH检测结果有助于预测多发性骨髓瘤患者预后。
Objective To explore and analyze the clinical therapeutic effect of ISS staging and FISH technology on patients with multiple myeloma and its prognosis.Methods From June 2014 to June 2018,91 patients with multiple myeloma admitted to our hospital were selected as clinical research objects.All the patients were given bortezomib for induction therapy.Retrospectively analyzed FISH test results,ISS stage,clinical curative effect and survival time.The laboratory index,clinical curative effect and survival time of multiple myeloma patients in different ISS stage were compared.And we analyzed the influence of ISS stage and FISH detection technique on the clinical therapeutic effect and prognosis of patients with multiple myeloma.Results Among the 91 cases of patients with multiple myeloma,20 patients in ISSⅠperiod,37 patients in ISSⅡperiod,34 patients in ISSⅢperiod.FISH positive detection rate and multiple FISH positive detection rate of patients in ISSⅢperiod were significantly higher than that of patients in ISSⅠperiod and ISSⅡperiod(P<0.05).FISH positive detection rate and multiple FISH positive detection rate of patients in ISS II period were significantly higher than that of patients in ISSⅠperiod(P<0.05).The complete remission rate of patients in ISS stageⅢperiod was significantly lower than the patients in ISS stageⅠand ISS stageⅡ(P<0.05).However,stability of disease condition in patients in ISS stageⅢperiod(P<0.05).The complete remission rate of patients in ISS stage II period was significantly lower than the patients in ISS stageⅠ,however,its stability of disease condition in patients in ISS stage I period,(P<0.05).The median survival time of patients in ISSⅢperiod was obviously shorter than the patients in ISSⅠand ISSⅡperiod(P<0.05),the median survival time of patients in ISSⅡperiod e was significantly shorter than that in patients in ISS stage I period(P<0.05),the differences were statistically significant.Pearson test analysis results showed that the ISS staging of patients with multiple myeloma was positively correlated to FISH positive rate,FISH multiple positive detection rate,condition stability the correlation coefficient r=0.5321,P<0.05.The ISS staging and clinical complete remission rate and the median survival time was negatively correlated,the correlation coefficient r=0.4432,P<0.05.The FISH positive detection rate of patients with multiple myeloma,clinical complete remission rate and the median survival time was negative correlated,the correlation coefficient r=0.3728,P<0.05.Conclusions The ISS staging of patients with multiple myeloma is positively correlated with FISH positive detection rate,multiple FISH positive detection rate,condition stability,and clinical complete remission rate,and negatively correlated with the median survival time and clinical complete remission rate.The positive detect rate of FISH was negatively correlated with the median survival time and clinical complete remission rate.The results of ISS staging and FISH test results helps predict the prognosis of patients with multiple myeloma.
作者
杨云
YANG Yun(Hematology department,Suzhou municipal hospital,Suzhou,Jiangsu,234000,China)
出处
《齐齐哈尔医学院学报》
2019年第2期144-147,共4页
Journal of Qiqihar Medical University
